Sign In
Last checked at 
24 Nov 2022 07:00
Sareum Holdings PLC
("Sareum" or the "Company")
Notice of AGM, Annual Report and Accounts
Cambridge, UK, 24 November 2022 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, today announces that the Company's Annual General Meeting ("AGM") will be held at 10.00 a.m. on 16 December 2022 at the offices of Peel Hunt LLP, 7th Floor, 100 Liverpool St, London EC2M 2AT.
The AGM will also be webcast via the Investor Meet Company ("IMC") platform. Shareholders who wish to follow the meeting via the IMC platform should register with IMC at www.investormeetcompany.com/sareum-holdings-plc/register-investor.
Shareholders are invited to listen to the meeting via the IMC platform and they will be able to raise questions with the Chairman, Chief Executive Officer and Chief Scientific Officer in a Q&A session to be held immediately after the AGM. Shareholders are reminded that this will not constitute attendance at the AGM and shareholders will not be able to vote on the day.
Shareholders intending to vote should do so via the shareholder portal at www.signalshares.com where details of the procedure are shown. Alternatively, shareholders may request a paper form of proxy from our registrars, Link Group.
The notice of AGM, along with a copy of the Company's annual report and accounts for the year ended 30 June 2022, will be posted today to those shareholders who requested a hard copy. A copy of both documents will also be available on the Company's website www.sareum.com.
- Ends -
For further information, please contact:
Sareum Holdings plc Tim Mitchell, CEO
Alexandra Harrison, Head of IR
|
01223 497700
ir@sareum.co.uk
|
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman
|
020 7409 3494 |
Peel Hunt LLP (Joint Corporate Broker) James Steel / Oliver Duckworth
|
020 7418 8900 |
Hybridan LLP (Joint Corporate Broker) Claire Noyce
|
020 3764 2341 |
Consilium Strategic Communications (Financial PR) Jessica Hodgson / Davide Salvi / Stella Lempidaki |
0203 709 5700 |
About Sareum
Sareum Holdings (AIM:SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases with an initial focus on psoriasis. Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com
Follow the stocks
